🇺🇸 FDA
Patent

US 10905769

Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use

granted A61KA61K31/519A61K31/585

Quick answer

US patent 10905769 (Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/519, A61K31/585, A61K47/64, A61K47/645